Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.

Lindsay M. Gurska,Rachel Okabe,Alexandra Schurer, Meng Maxine. Tong, Mark Soto,Daniel Choi,Kristina Ames,Shira Glushakow-Smith,Allison Montoya,Ellen Tein,Linde A. Miles,Haiying Cheng, Pamela Giblin,Ross L. Levine,Swati Goel,Balazs Halmos,Kira Gritsman

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览29

暂无评分

摘要

In summary, we demonstrate that crizotinib has preclinical efficacy in MPN patient cells, JAK2-mutated cell lines, and a JAK2-mutated mouse model, and that the combination of crizotinib with JAK inhibitors suppresses JAK inhibitor persistence. Our work suggests that crizotinib should be investigated for the treatment of patients with MPN.

查看译文

关键词

crizotinib,philadelphia-negative

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要